1) Welcome and Rollcall

I. Welcome:
Meeting opened by Sharisse Kemp, ADAP Branch Chief

II. Introductions:
MAC Members, CDPH and Magellan introduced themselves

MAC Members in Attendance

MAC Members not in Attendance
Jennefer Yoon

CDPH/Office of AIDS staff in Attendance
Philip Peters, Sharisse Kemp, Ann Nakamura, Becca Parks, James Vo

Magellan Representatives in Attendance
Jason Eugenio, Carrie Holden

2) ADAP / MAC Updates

I. Medications added to the ADAP formulary:
   • Generic Seroquel added to the ADAP formulary.
   • Removal of brand preferencing policy for antiretrovirals.
   • Expanded reimbursement for Cabenuva, ADAP funding will be used to reimburse the injection administration fee and clinic visits for approved clinical providers.

II. Medications removed from the ADAP formulary
   • None

III. Update on the medications discussed during the January 2021 MAC meeting:
   • Hypertension, oral contraceptives, and opportunistic infection medications are currently being reviewed.

3) Medication Discussion

I. No New ARVs have received FDA approval

II. Cabenuva (Cabotegravir/Rilpivirine)
- Lucas Hill (Presentation): Review of Long-Acting Injection Cabotegravir/Rilpivirine and Real-World Experience

III. No public comments received

4) **Opportunistic Infection Treatments**
   - John Openshaw (presentation): COVID-19 outpatient therapeutics

5) **Magellan Rx Presentation**
   - Carrie Holden (presentation): Hold until next MAC meeting

6) **Close of Meeting**
   I. The next ADAP MAC meeting is scheduled for July 20, 2022, from 7:30 a.m. to 9:00 a.m.

7) **Action Items**

<table>
<thead>
<tr>
<th>Action Items</th>
<th>Owners</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discussion of Islatravir and diabetes treatment at the next MAC meeting in July.</td>
<td>Dr. Peters/James Vo</td>
</tr>
</tbody>
</table>